Xenon Pharmaceuticals (XENE) Free Cash Flow (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Free Cash Flow of -$89.0 million for Q1 2026, down 44.31% year-over-year from -$159.9 million in Q1 2025, and down 8.84% quarter-over-quarter from -$81.8 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Free Cash Flow (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Free Cash Flow data on file, last reported at -$89.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$89.0 million, down 44.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$307.3 million (down 53.79% YoY), and the FY2025 annual result was -$279.9 million, down 51.75% from the prior year.
- Free Cash Flow fell to -$89.0 million in Q1 2026 per XENE's latest filing, from -$81.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$17.4 million in Q2 2022 and troughed at -$89.0 million in Q1 2026.
- A 5-year average of -$47.9 million and a median of -$46.4 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow advanced 11.71% in 2022, then slumped 103.04% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$37.1 million in 2022, then climbed by 4.32% to -$35.5 million in 2023, then sank by 55.49% to -$55.2 million in 2024, then plunged by 48.27% to -$81.8 million in 2025, then dropped by 8.84% to -$89.0 million in 2026.
- Business Quant data shows XENE's Free Cash Flow at -$89.0 million in Q1 2026, -$81.8 million in Q4 2025, and -$72.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -89.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89.03 Mn |
| Mar 31, 2026 | -89.03 Mn |
| Dec 31, 2025 | -81.80 Mn |
| Dec 31, 2025 | -81.80 Mn |
| Sep 30, 2025 | -72.03 Mn |
| Sep 30, 2025 | -72.03 Mn |
| Jun 30, 2025 | -64.39 Mn |
| Jun 30, 2025 | -64.39 Mn |
| Mar 31, 2025 | -61.70 Mn |
| Mar 31, 2025 | -61.70 Mn |
| Dec 31, 2024 | -55.17 Mn |
| Dec 31, 2024 | -55.17 Mn |
| Sep 30, 2024 | -50.26 Mn |
| Sep 30, 2024 | -50.26 Mn |
| Jun 30, 2024 | -32.67 Mn |
| Jun 30, 2024 | -32.67 Mn |
| Mar 31, 2024 | -46.38 Mn |
| Mar 31, 2024 | -46.38 Mn |
| Dec 31, 2023 | -35.48 Mn |
| Dec 31, 2023 | -35.48 Mn |